NCT07230106 2026-03-03
A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Recruiting
Clinical Trials
10 trialsNCT06241846 2025-08-27
A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPC
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 2 Recruiting
NCT06387056 2024-04-26
SEGNO
The First Affiliated Hospital of Xiamen University
Phase 2 Recruiting
NCT04028388 2024-04-17
ModraDoc006/r vs Docetaxel IV in Metastatic Prostate Cancer
Modra Pharmaceuticals
Phase 2 Completed
NCT04073602 2023-12-18
A Study of RC48-ADC in Subjects With HER2-negative Locally Advanced or Metastatic Urothelial Cancer
RemeGen Co., Ltd.
Phase 2 Completed
NCT03809013 2023-11-27
A Open-label, Single-arm, Multicenter, Phase II Study of RC48-ADC to Evaluate the Efficacy and Safety of Subjects With HER2 Overexpressing Locally Advanced or Metastatic Urothelial Cancer
RemeGen Co., Ltd.
Phase 2 Completed
NCT04272645 2020-07-15
Abemaciclib With or Without Atezolizumab in Metastatic Castration Resistant Prostate Cancer
University of Michigan Rogel Cancer Center
Phase 2 Withdrawn
NCT03507166 2019-08-21
A Phase II Study of RC48-ADC in Subjects With HER2 Positive Metastatic or Unresectable Urothelial Cancer
RemeGen Co., Ltd.
Phase 2 Completed
NCT02584400 2019-03-08
HX4 SD
Maastricht Radiation Oncology
Phase 2 Terminated
NCT00918281 2014-06-09
Reproducibility of 18F Uptake by Solid Tumors Using PET Imaging Following Intravenous Administration of (18F) Injection
GE Healthcare
Phase 2 Completed